BioSpace News Archive

Enanta Pharmaceuticals, Inc. today provides an update on its two clinical stage farnesoid X receptor (FXR) agonists, EDP-305 and EDP-297, for the treatment of non-alcoholic steatohepatitis (NASH).

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced completion of a $25 million long-term debt facility led by Horizon Technology Finance Corporation (Nasdaq: HRZN) (“Horizon”).

Oragenics, Inc. today announced that it was awarded a small business innovation research grant in the amount of $250,000 (“Computer-aided Design for Improved Lantibiotics” R41GM136034) for the Company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University

Novocure and Zai Lab Limited today announced that the final patient has been enrolled in a Novocure-sponsored phase 2 pilot trial conducted by Zai Lab evaluating the safety and efficacy of Tumor Treating Fields (TTFields) in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma.

Arch Therapeutics, Inc. today announced the launch of its coverage and reimbursement pilot (the “Pilot”) in collaboration with The Reimbursement Group (“TRG”) for the Company’s AC5 ® Advanced Wound System.

Cognition Therapeutics, Inc. today announced that it has launched an initial public offering of 3,350,000 shares of its common stock.

Selecta Biosciences, Inc. today announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to develop targeted, next-generation gene therapies for two indications within the field of lysosomal storage disoorders.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the appointment of Alan Ashworth, Ph.D., FRS, a world-renowned expert in cancer research and a global leader in cancer therapy development, to the company’s board of directors.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), today announced that it presented results from a preclinical study of KER-012 at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting held October 1 through 4, 2021.